Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase
Minke A.E. Rab(Utrecht University), Richard van Wijk(Utrecht University), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Stephanie van Straaten(Utrecht University), Brigitte A. van Oirschot(Utrecht University), Jennifer Bos(Utrecht University), Eduard J. van Beers(Utrecht University), Charles Kung(Agios Pharmaceuticals (United States)), Bart J. Biemond(Amsterdam UMC Location University of Amsterdam)
Cited by 18
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores
|Nature Cell Biology|2005|292
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
|Nature Chemical Biology|2007|203
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162